Adeptus Biotechnologies stock initiated with buy rating at Craig-Hallum

Craig-Hallum initiated coverage of Adaptive Biotechnologies (ADPT) with a buy rating and a $15 price target, citing the company's leadership in blood cancer MRD testing with its FDA-approved clonoSEQ assay and a $1.8 billion market opportunity. This follows Adaptive's strong Q1 performance, with revenue of $52.44 million exceeding estimates and a 25% year-over-year increase driven by a 34% rise in MRD business revenue, prompting BTIG to raise its price target to $11.00 and express confidence in the company's path to positive adjusted EBITDA in its MRD business by the second half of 2025.

Analysis

Craig-Hallum has initiated coverage on Adaptive Biotechnologies (ADPT) with a buy rating and a $15.00 price target, identifying the company as a leader in minimal residual disease (MRD) testing for hematologic malignancies with its clonoSEQ assay, the sole FDA-approved test in this category. This assessment is significant given the clonoSEQ's target market, valued at $1.8 billion, and the stock's impressive 229% return over the past year, currently trading near its 52-week high of $10.87, while other analysts maintain a bullish consensus with price targets ranging from $9 to $13. Adaptive Biotechnologies' strong first-quarter performance, featuring a smaller-than-expected loss per share of ($0.20) and revenue of $52.44 million—a 25% year-over-year increase primarily driven by a 34% rise in MRD business revenue—surpassed the forecasted $42.81 million. Following these results, the company raised its full-year MRD revenue guidance to between $180 million and $190 million, and BTIG analysts increased their stock price target to $11.00, maintaining a Buy rating and expressing confidence in Adaptive's trajectory toward positive adjusted EBITDA in its MRD business by the second half of 2025. Further reinforcing its market position, the clonoSEQ test is set to be featured in 30 scientific presentations at upcoming medical meetings.

Key Decisions for Investors

• The initiation of coverage by Craig-Hallum with a $15.00 price target, alongside BTIG's increased target of $11.00 and strong Q1 results including a 25% YoY revenue growth and raised full-year MRD guidance, signal a robust positive outlook for Adaptive Biotechnologies.
• Investors should monitor the company's progress towards achieving its stated goal of positive adjusted EBITDA in the MRD business by H2 2025, as this is a key catalyst for further valuation uplift.
• While the stock has achieved a significant 229% return in the past year and trades near its 52-week high, the unique FDA-approved status of clonoSEQ in a $1.8 billion market and upcoming scientific showcases suggest potential for continued growth, warranting careful consideration of entry points or holding existing positions.